In this study, we evaluated a novel combination of drug delivery devices composed of holo-transferrin conjugated liposomes for siRNA (36 nM) delivery, and electrospun polycaprolactone (PCL)-gelatin (GT) microfibers for resveratrol (40 µM) release. Single- and co-cultures of cancerous K562 cells and human umbilical vein endothelial cells (HUVECs) were used to test the efficacy and targeting over eight days. BCR-ABL siRNA-encapsulated (36 nM) holo-transferrin-conjugated PEG-liposomes were characterized using dynamic light scattering, and transmission electron microscopy. RT-qPCR was performed to assess the silencing BCR-ABL gene. Two treatment protocols were explored: i) simultaneous administration ii) delayed liposomes addition by three days based on resveratrol release profile. Formed liposomes were 123 (±6.65) nm in diameter, holo-transferrin conjugation efficiency was 85.9 (±7.30)%, and siRNA loading efficiency was 92.3 (±2.57)%. Sphingosine-1-phosphate (S1P) content was analyzed by ELISA. Targeted siRNA release in combination with resveratrol release was more potent and has long-term effects compared to bolus doses. Delayed addition of liposomes increased non-viability of K562 cells to 92.7 (±2.00)% and 94.32 (±1.70)%, in the absence and presence of HUVECs, respectively. HUVECs non-viability level was significantly lower. Using two different delivery devices approach has a broader impact on cancer treatment.
Keywords: Apoptosis; Combination therapy; Drug delivery; Electrospinning; Liposomes; Resveratrol; siRNA.
Copyright © 2019 Elsevier B.V. All rights reserved.